Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8412051 | 0.89 | CYP2C19 (0.44) | CYP2C19NPSR1DGAT1ALDH1A1POLB | |
| SCHEMBL27853892 | 0.81 | ALDH1A1 (0.43) | CYP2C19ALDH1A1TSHR | |
| SCHEMBL3950466 | 0.75 | CYP2C19 (0.44) | CYP2C19NPSR1DGAT1ALDH1A1POLB | |
| SCHEMBL19283840 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL17674169 | 0.72 | CYP2C19 (0.42) | CYP2C19NPSR1DGAT1ALDH1A1POLB | |
| SCHEMBL23829928 | 0.68 | CYP2C19 (0.40) | CYP2C19NPSR1DGAT1ALDH1A1POLB | |
| SCHEMBL10574153 | 0.68 | CYP2C19 (0.40) | CYP2C19NPSR1DGAT1ALDH1A1POLB | |
| SCHEMBL7872758 | 0.66 | ALDH1A1 (0.43) | CYP2C19ALDH1A1TSHR | |
| SCHEMBL1010735 | 0.66 | DGAT1 (0.56) | CYP2C19DGAT1ALDH1A1KCNN4TSHR | |
| SCHEMBL5593709 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | CYP2C19 1555/4885NPSR1 2664/4885DGAT1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.